New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: Studies on growth, metabolism and virus propagation

Vaccine

Volumn 27, Issue 36, 2009, Pages 4975-4982

  Lohr, V ^a   Rath, A ^a   Genzel, Y ^a   Jordan, I ^b   Sandig, V ^b   Reichl, U ^a,c  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b PROBIOGEN AG   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

AGE1.CR; Avian designer cell; Influenza virus; Modified vaccinia virus Ankara; Serum free medium; Specific rates; Suspension cell; Vaccine production; Wave bioreactor

Indexed keywords

ARTICLE; BIOREACTOR; CELL GROWTH; CELL LINE; CELL METABOLISM; CULTURE MEDIUM; FOWL; HOST CELL; INFLUENZA VIRUS; MODIFIED VACCINIA VIRUS ANKARA; NONHUMAN; PRIORITY JOURNAL; SUSPENSION CELL CULTURE; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS CULTURE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BIRDS; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA, SERUM-FREE; HUMANS; ORTHOMYXOVIRIDAE; VACCINIA VIRUS;

EID: 67650430190     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.083     Document Type: Article

References (32)

1. Robertson J.S., Cook P., Attwell A.M., and Williams S.P. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine 13 16 (1995) 1583-1588
2. Merten O.W., Hannoun C., Manuguerra J.C., Ventre F., and Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 397 (1996) 141-151
3. Sandig V., Jordan I. Immortalized avian cell lines for virus production. WO 2005/042728 A2, 2005.
4. Mehtali M., Chamion-Arnaud P., Leon A. Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines. WO 2006/108846 A1, 2006.
5. Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J., Hehir K.M., Keegan J., et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9 13 (1998) 1909-1917
6. Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., and Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19 17-19 (2001) 2716-2721
7. Guehenneux F., Pain B.; Production of poxviruses with adherent or non adherent avian cell lines. WO 2005/007840 A1, 2005.
8. Hussain A.I., Johnson J.A., Da Silva Freire M., and Heneine W. Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J Virol 77 2 (2003) 1105-1111
9. Shoyab M., and Baluda M.A. Homology between avian oncornavirus RNAs and DNA from several avian species. J Virol 16 6 (1975) 1492-1502
10. Jordan I., Vos A., Beilfuss S., Neubert A., Breul S., and Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 27 5 (2009) 748-756
11. Kalbfuss B., Knochlein A., Krober T., and Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 36 3 (2008) 145-161
12. Genzel Y., Ritter J.B., König S., Alt R., and Reichl U. Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol Prog 21 1 (2005) 58-69
13. Genzel Y., Behrendt I., König S., Sann H., and Reichl U. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 22 17-18 (2004) 2202-2208
14. Miwa H., Fujii J., Kanno H., Taniguchi N., and Aozasa K. Pyruvate secreted by human lymphoid cell lines protects cells from hydrogen peroxide mediated cell death. Free Radical Res 33 1 (2000) 45-56
15. Maranga L., Aunins J.G., and Zhou W. Characterization of changes in PER.C6 cellular metabolism during growth and propagation of a replication-deficient adenovirus vector. Biotechnol Bioeng 90 5 (2005) 645-655
16. Merten O.W., Kierulff J.V., Castignolles N., and Perrin P. Evaluation of the new serum-free medium (MDSS2) for the production of different biologicals: use of various cell lines. Cytotechnology 14 1 (1994) 47-59
17. Han Y., Liu X.M., Liu H., Li S.C., Wu B.C., Ye L.L., et al. Cultivation of recombinant Chinese hamster ovary cells grown as suspended aggregates in stirred vessels. J Biosci Bioeng 102 5 (2006) 430-435
18. Genzel Y., Olmer R.M., Schäfer B., and Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 24 35-36 (2006) 6074-6087
19. Tree J.A., Richardson C., Fooks A.R., Clegg J.C., and Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19 25-26 (2001) 3444-3450
20. Rimmelzwaan G.F., Baars M., Claas E.C., and Osterhaus A.D. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 74 1 (1998) 57-66
21. Ozaki H., Govorkova E.A., Li C., Xiong X., Webster R.G., and Webby R.J. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol 78 4 (2004) 1851-1857
22. Merten O.W., Manuguerra J.C., Hannoun C., and van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 98 (1999) 23-37 discussion 73-4
23. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 9-10 (1998) 960-968
24. Ward B.M. The longest micron; transporting poxviruses out of the cell. Cell Microbiol 7 11 (2005) 1531-1538
25. Smith G.L., Vanderplasschen A., and Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83 12 (2002) 2915-2931
26. Spehner D., Drillien R., Proamer F., Houssais-Pecheur C., Zanta M.A., Geist M., et al. Enveloped virus is the major virus form produced during productive infection with the modified vaccinia virus Ankara strain. Virology 273 1 (2000) 9-15
27. Melville M.W., Tan S.L., Wambach M., Song J., Morimoto R.I., and Katze M.G. The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity. J Biol Chem 274 6 (1999) 3797-3803
28. Gilbert P.A., Comanita L., Barrett J., Peters A., Szabat M., McFadden G., et al. Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development. Cytotechnology 48 (2005) 79-88
29. Meiser A., Boulanger D., Sutter G., and Krijnse Locker J. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release. J Gen Virol 84 6 (2003) 1383-1392
30. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 2 (1998) 347-352
31. Carroll M.W., and Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238 2 (1997) 198-211
32. Ozturk S.S., and Palsson B.O. Growth, metabolic, and antibody production kinetics of hybridoma cell culture: 1. Analysis of data from controlled batch reactors. Biotechnol Prog 7 6 (1991) 471-480